Wedbush Brokers Raise Earnings Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at Wedbush raised their FY2026 earnings per share (EPS) estimates for Travere Therapeutics in a report released on Tuesday, May 7th. Wedbush analyst L. Chico now expects that the company will earn $0.92 per share for the year, up from their previous estimate of $0.82. Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2027 earnings at $0.24 EPS.

Other equities research analysts have also issued research reports about the company. Piper Sandler boosted their price objective on Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, January 18th. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Wells Fargo & Company upped their price target on Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Friday, February 16th. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Travere Therapeutics in a research note on Tuesday. Finally, Canaccord Genuity Group upped their target price on Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.69.

Travere Therapeutics Price Performance

NASDAQ TVTX traded down $0.17 during midday trading on Friday, hitting $6.43. The company had a trading volume of 100,152 shares, compared to its average volume of 1,268,153. The company has a market capitalization of $489.39 million, a PE ratio of -4.10 and a beta of 0.69. The company has a current ratio of 3.47, a quick ratio of 3.41 and a debt-to-equity ratio of 1.88. The firm has a 50-day moving average price of $6.97 and a 200-day moving average price of $7.59. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $19.54.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The company had revenue of $41.40 million during the quarter, compared to the consensus estimate of $43.46 million. During the same quarter in the prior year, the business earned ($1.27) earnings per share. The firm’s revenue for the quarter was up 34.0% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TVTX. Avidity Partners Management LP purchased a new position in shares of Travere Therapeutics during the 3rd quarter worth approximately $11,828,000. Kynam Capital Management LP grew its holdings in shares of Travere Therapeutics by 105.6% during the 4th quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock worth $17,980,000 after acquiring an additional 1,027,398 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Travere Therapeutics in the 4th quarter worth approximately $5,711,000. Finepoint Capital LP boosted its position in shares of Travere Therapeutics by 60.2% in the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock worth $12,904,000 after purchasing an additional 539,500 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Travere Therapeutics by 10.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock worth $41,727,000 after purchasing an additional 460,176 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.